NIKKEI 225
38,166.72 -35.65 (-0.09%) HANG SENG
18,556.64 +242.78 (+1.33%) CRUDE OIL
79.37 +0.38 (+0.48%) GOLD FUTURES
2,322.70 +0.40 (+0.02%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,303.95 -801.32 (-1.60%)
MeiraGTx Holdings plc (328.F)
| Previous close | 4.6000 |
| Open | 4.9000 |
| Bid | 4.7200 x N/A |
| Ask | 4.8600 x N/A |
| Day's range | 4.9000 - 4.9000 |
| 52-week range | 3.2600 - 7.4000 |
| Volume | |
| Avg. volume | 236 |
| Market cap | 341.642M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, Virtual Corporate presentation: Monday, April 29, 2024, at 11:00 a.m. ET BofA Securities Healthcare Conference 2024, Las Vegas
- GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL. The details of the oral presentation are below: Session: Oral Abstract Session IPresentation ID #196Title: Results of a Phase 1, Open-label, Dos
- GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing - Company to present data from the Phase 1 AQUAx study in an oral presentation at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Completed dosing the three-arm randomized, sham-controlled Phase 1 clinical bridging study for AAV-GAD for the treatment of Parkinson’s disease - Co
